Icatibanto Piramal

Icatibant, the active ingredient in Icatibanto Piramal, is a Bradykinin B2 receptor antagonist presented as a solution for subcutaneous injection use. It treats hereditary angioedema (C1 inhibitor deficiency) by reducing swelling during acute attacks in affected patients.

GNH USA supplies Icatibanto Piramal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for hereditary angioedema, acting on the bradykinin pathway to control swelling.

Hereditary angioedema (C1‑INH deficiency): reduces the severity and duration of acute swelling episodes. Hereditary angioedema type I: provides rapid relief of cutaneous and submucosal edema. Hereditary angioedema type II: diminishes attack intensity and shortens recovery time.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain or erythema - Local swelling or induration - Nausea or mild vomiting - Headache or dizziness - Transient flushing - Fatigue or malaise

Serious or Rare Side Effects: - Anaphylactic reaction - Severe angioedema unrelated to disease - Hypotension or shock - Urticaria or widespread rash - Thrombotic events - Acute respiratory distress

Before using Icatibant, consider the following safety measures.

Renal impairment: monitor renal function and adjust clinical observation. Hepatic impairment: use with caution and observe for altered metabolism. Pregnancy: safety not established; avoid unless benefits outweigh risks. Breastfeeding: unknown excretion; weigh potential infant exposure. Concomitant ACE inhibitors: may increase bradykinin‑related effects, monitor closely. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other agents that influence bradykinin metabolism or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may potentiate bradykinin accumulation and raise angioedema risk. - Neprilysin inhibitors (e.g., sacubitril): increase bradykinin levels, heightening swelling potential. - Renin‑angiotensin system blockers: additive edema risk, require close monitoring.

Moderate Interactions (Monitor Closely): - C1‑esterase inhibitor concentrates: may affect overall efficacy if given simultaneously. - Antihistamines: could mask early signs of hypersensitivity. - Systemic corticosteroids: may alter inflammatory response, necessitating observation.